Pharming Group (NASDAQ:PHAR) Short Interest Update

Pharming Group (NASDAQ:PHAR - Get Free Report) was the target of a significant decline in short interest in March. As of March 31st, there was short interest totalling 2,500 shares, a decline of 56.9% from the March 15th total of 5,800 shares. Based on an average daily trading volume, of 6,500 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.0% of the company's shares are sold short.

Pharming Group Stock Up 4.6 %

Shares of NASDAQ:PHAR traded up $0.38 during trading hours on Monday, reaching $8.47. The stock had a trading volume of 326 shares, compared to its average volume of 6,277. Pharming Group has a 1 year low of $6.65 and a 1 year high of $11.07. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The stock has a market capitalization of $575.88 million, a price-to-earnings ratio of -32.56 and a beta of -0.08. The firm's 50 day moving average is $8.52 and its 200-day moving average is $8.69.

Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its earnings results on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The business had revenue of $92.70 million for the quarter, compared to analysts' expectations of $76.67 million. Research analysts predict that Pharming Group will post -0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its position in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 47,997 shares of the company's stock after buying an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 0.03% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on PHAR shares. HC Wainwright restated a "buy" rating and issued a $37.00 price objective on shares of Pharming Group in a report on Thursday, March 20th. Oppenheimer lifted their target price on Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a report on Friday, March 14th.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.